Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Want to cut your energy bills? Here’s how five experts are doing it 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
NEW YORK, March 11, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PTC Therapeutics, Inc. (NASDAQ:PTCT) securities between May 6, 2014 and February 23, 2016.
Click here to learn about the case: http://docs.wongesq.com/PTCT-Info-Request-Form-1135. There is no cost or obligation to you.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. According to the Complaint, on February 23, 2016, PTC announced that it received a Refuse to File letter from the United States Food and Drug Administration (“FDA”) regarding the New Drug Application for Translarna. The FDA stated in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review. On this news, shares of PTC fell over 61%, closing at $10.84 per share on February 23, 2016, on heavy trading volume.
If you suffered a loss in PTC you have until May 2, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/PTCT-Info-Request-Form-1135.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
